Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kidney Res Clin Pract. 2013 Sep;32(3):138-41. doi: 10.1016/j.krcp.2013.06.003. Epub 2013 Jul 17.
Idiopathic membranous nephropathy is a common cause of nephrotic syndrome, and has been reported as a cause of idiopathic primary glomerulonephropathy in up to 90% of patients. However, the treatment options remain controversial. We report two cases of idiopathic membranous nephropathy that were treated with rituximab. A 54-year-old man and a 64-year old man were admitted for rituximab therapy. They had previously been treated with combinations of immunosuppressive agents including cyclophosphamide, cyclosporine, mycophenolate, and steroids. However, the patients' heavy proteinuria was not resolved. Both patients received rituximab therapy, 2 weeks apart. After several months of follow-up and a second round of rituximab treatment for each patient, their proteinuria decreased and partial remission of disease was achieved in both patients.
特发性膜性肾病是肾病综合征的常见病因,在高达 90%的患者中被报告为特发性原发性肾小球肾炎的病因。然而,治疗选择仍存在争议。我们报告了两例特发性膜性肾病患者接受利妥昔单抗治疗的情况。一名 54 岁男性和一名 64 岁男性因接受利妥昔单抗治疗而入院。他们之前曾接受过包括环磷酰胺、环孢素、霉酚酸酯和类固醇在内的免疫抑制剂联合治疗。然而,患者的大量蛋白尿并未得到解决。两名患者均接受了利妥昔单抗治疗,间隔 2 周。经过数月的随访和每位患者的第二轮利妥昔单抗治疗,他们的蛋白尿减少,两名患者的疾病均部分缓解。